 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for NR1I3 |
 Gene summary |
| Basic gene information | Gene symbol | NR1I3 |
| Gene name | nuclear receptor subfamily 1, group I, member 3 | |
| Synonyms | CAR|CAR1|MB67 | |
| Cytomap | UCSC genome browser: 1q23.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001077469.2, NM_001077470.2,NM_001077471.2,NM_001077472.2,NM_001077473.2, NM_001077474.2,NM_001077475.2,NM_001077476.2,NM_001077477.2, NM_001077478.2,NM_001077479.2,NM_001077480.2,NM_001077481.2, NM_001077482.2,NM_005122.4, | |
| Description | constitutive activator of retinoid responseconstitutive active receptorconstitutive active responseconstitutive androstane nuclear receptor variant 2constitutive androstane nuclear receptor variant 3constitutive androstane nuclear receptor variant 4 | |
| Modification date | 20141211 | |
| dbXrefs | MIM : 603881 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000143257 | ||
| HPRD : 04858 | ||
| Vega : OTTHUMG00000034347 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_NR1I3 | |
| BioGPS: 9970 | ||
| Pathway | NCI Pathway Interaction Database: NR1I3 | |
| KEGG: NR1I3 | ||
| REACTOME: NR1I3 | ||
| Pathway Commons: NR1I3 | ||
| Context | iHOP: NR1I3 | |
| ligand binding site mutation search in PubMed: NR1I3 | ||
| UCL Cancer Institute: NR1I3 | ||
| Assigned class in TissGDB* | B | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | KidneyLiver | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | KIRC,KIRP,KICHLIHC | |
| Reference showing the relevant tissue of NR1I3 | ||
| Description by TissGene annotations | Protective TissGene in RFS TissgsKTS CNV lost TissGeneKTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 11114890 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 11114890 |
| Top |
| TissGeneExp for NR1I3 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LIHC | 4.885075245 | 6.708181245 | -1.823106 | 2.18E-05 | 8.57E-05 |
| KICH | -1.278260755 | 0.848423245 | -2.126684 | 1.93E-06 | 6.96E-06 |
| KIRP | -1.27102063 | 1.53571062 | -2.80673125 | 3.44E-12 | 5.14E-11 |
| KIRC | -1.594907089 | 0.768958189 | -2.363865278 | 5.47E-19 | 3.92E-18 |
| Top |
| TissGene-miRNA for NR1I3 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for NR1I3 |
| TissGeneSNV for NR1I3 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.E54K | SKCM | 2 |
| p.F167S | SARC | 1 |
| p.R301* | LUAD | 1 |
| p.R183L | CHOL | 1 |
| p.R250Q | SKCM | 1 |
| p.E200K | SKCM | 1 |
| p.R254Q | BLCA | 1 |
| p.G332S | SKCM | 1 |
| p.E280K | LUAD | 1 |
| p.F167L | UCEC | 1 |
| p.D282N | SKCM | 1 |
| p.G280E | SKCM | 1 |
| p.M340K | LUAD | 1 |
| p.A50D | LUAD | 1 |
| p.D189N | BLCA | 1 |
| p.R183H | LUAD | 1 |
| p.R145K | SARC | 1 |
| p.A120V | COAD | 1 |
| p.L293Q | KIRC | 1 |
| p.C63Y | BLCA | 1 |
| p.A25V | READ | 1 |
| p.S42R | LIHC | 1 |
| p.G280R | LUAD | 1 |
| p.R61H | UCEC | 1 |
| p.K32N | PRAD | 1 |
| p.T116K | SKCM | 1 |
| p.L91I | UCEC | 1 |
| p.G241E | SKCM | 1 |
| p.G259S | SKCM | 1 |
| p.P331S | UCEC | 1 |
| p.G314E | SKCM | 1 |
| p.R123H | READ | 1 |
| p.C31F | LUAD | 1 |
| p.A267P | LIHC | 1 |
| p.R308Q | UCEC | 1 |
| p.F217L | LUSC | 1 |
| p.F129S | UCEC | 1 |
| p.R250Q | BLCA | 1 |
| p.R310* | BRCA | 1 |
| p.R223H | LGG | 1 |
| p.D291N | SKCM | 1 |
| p.A99T | STAD | 1 |
| p.P331S | STAD | 1 |
| p.T122I | GBM | 1 |
| p.A336T | SKCM | 1 |
| p.Q110H | STAD | 1 |
| p.K32T | CHOL | 1 |
| p.W96* | SKCM | 1 |
| p.E256K | TGCT | 1 |
| p.Y337H | COAD | 1 |
| p.G232V | BLCA | 1 |
| p.E260K | TGCT | 1 |
| p.L206F | PAAD | 1 |
| p.S40C | LUAD | 1 |
| p.R329W | UCEC | 1 |
| p.L284Q | KIRC | 1 |
| p.P234H | STAD | 1 |
| p.A84T | STAD | 1 |
| p.V232L | COAD | 1 |
| Top |
| TissGeneCNV for NR1I3 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for NR1I3 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for NR1I3 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CYP3A4, ADH1B, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| NR1I3, HNF4A, SRC, NR0B2, NCOA1, RARB, EP300, EIF3I, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, NOS2, PPARGC1A, ALAS1, MED1, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, POU1F1, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, CYP2B6, SNX13 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| NR1I3, HNF4A, SRC, NR0B2, RXRA, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, POU1F1, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CYP3A4, POU1F1, ADH1B, CYP2B6 (tumor) | NR1I3, NR3C1, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, MED1, MAP4, CYP2C9, CHD9, CYP3A4, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, CYP2C9, CYP3A4, POU1F1, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, ALAS1, MED1, CYP2C9, CHD9, CYP3A4, POU1F1, CYP2B6, SNX13 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, ADH1B, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, PPARGC1A, ALAS1, MED1, CYP2C9, CHD9, CYP3A4, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, NCOA1, RARB, EP300, EIF3I, FTH1, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, POU1F1, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, NR0B2, RXRA, RARB, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, ADH1B, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, SRC, NR0B2, NCOA1, RARB, EP300, EIF3I, FTH1, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, CYP2B6, SNX13 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6 (tumor) | NR1I3, NR3C1, HNF4A, NR0B2, RXRA, NCOA1, EP300, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, CYP3A4, POU1F1, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| NR1I3, NR3C1, HNF4A, SRC, NR0B2, RXRA, NCOA1, RARB, EP300, EIF3I, FTH1, SNRPD3, PPARGC1A, ALAS1, MED1, CYP2C9, CHD9, CYP3A4, ADH1B, CYP2B6, SNX13 (tumor) | NR1I3, NR3C1, HNF4A, NR0B2, RXRA, NCOA1, EP300, EIF3I, FTH1, NOS2, SNRPD3, PPARGC1A, ALAS1, MED1, MAP4, CYP2C9, CHD9, POU1F1, ADH1B, CYP2B6, SNX13 (normal) |
 |  |
| Top |
| TissGeneProg for NR1I3 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for NR1I3 |
| TissGeneDrug for NR1I3 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for NR1I3 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0023418 | leukemia | 8 | BeFree |
| umls:C0023903 | Liver neoplasms | 8 | BeFree,CTD_human |
| umls:C2239176 | Liver carcinoma | 7 | BeFree,LHGDN |
| umls:C0006142 | Malignant neoplasm of breast | 6 | BeFree |
| umls:C0678222 | Breast Carcinoma | 6 | BeFree |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 5 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 5 | BeFree |
| umls:C0023434 | Chronic Lymphocytic Leukemia | 4 | BeFree |
| umls:C0028754 | Obesity | 4 | BeFree,CTD_human |
| umls:C0029925 | Ovarian Carcinoma | 4 | BeFree |
| umls:C0280100 | Solid tumour | 4 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 4 | BeFree |
| umls:C0596263 | Carcinogenesis | 4 | BeFree |
| umls:C0600139 | Prostate carcinoma | 4 | BeFree |
| umls:C1140680 | Malignant neoplasm of ovary | 4 | BeFree |
| umls:C0002395 | Alzheimer's Disease | 3 | BeFree |
| umls:C0008370 | Cholestasis | 3 | BeFree |
| umls:C0009402 | Colorectal Carcinoma | 3 | BeFree |
| umls:C0019209 | Hepatomegaly | 3 | CTD_human |
| umls:C0023530 | Leukopenia | 3 | BeFree,GAD |
| umls:C0023904 | Liver Neoplasms, Experimental | 3 | CTD_human |
| umls:C0025517 | Metabolic Diseases | 3 | BeFree |
| umls:C0027819 | Neuroblastoma | 3 | BeFree |
| umls:C0342345 | Hypoparathyroidism - autosomal dominant | 3 | BeFree |
| umls:C0376545 | Hematologic Neoplasms | 3 | BeFree |
| umls:C0700095 | Central neuroblastoma | 3 | BeFree |
| umls:C1527249 | Colorectal Cancer | 3 | BeFree |
| umls:C0004114 | Astrocytoma | 2 | BeFree |
| umls:C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 2 | BeFree |
| umls:C0019348 | Herpes Simplex Infections | 2 | BeFree |
| umls:C0019693 | HIV Infections | 2 | BeFree |
| umls:C0020433 | Hyperbilirubinemia | 2 | BeFree |
| umls:C0020626 | Hypoparathyroidism | 2 | BeFree |
| umls:C0020676 | Hypothyroidism | 2 | BeFree |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 2 | BeFree |
| umls:C0024299 | Lymphoma | 2 | BeFree |
| umls:C0025202 | melanoma | 2 | BeFree |
| umls:C0027947 | Neutropenia | 2 | BeFree,GAD |
| umls:C0032927 | Precancerous Conditions | 2 | CTD_human |
| umls:C0085110 | Severe Combined Immunodeficiency | 2 | BeFree |
| umls:C0860207 | Drug-Induced Liver Injury | 2 | CTD_human |
| umls:C1261473 | Sarcoma | 2 | BeFree |
| umls:C1292769 | Precursor B-cell lymphoblastic leukemia | 2 | BeFree |
| umls:C0001430 | Adenoma | 1 | BeFree |
| umls:C0003873 | Rheumatoid Arthritis | 1 | BeFree |
| umls:C0007102 | Malignant tumor of colon | 1 | BeFree |
| umls:C0007113 | Rectal Carcinoma | 1 | BeFree |
| umls:C0007193 | Cardiomyopathy, Dilated | 1 | BeFree |
| umls:C0008372 | Intrahepatic Cholestasis | 1 | BeFree |
| umls:C0011849 | Diabetes Mellitus | 1 | CTD_human |
| umls:C0011853 | Diabetes Mellitus, Experimental | 1 | RGD |
| umls:C0017638 | Glioma | 1 | BeFree |
| umls:C0019034 | Hemoglobin SC Disease | 1 | BeFree |
| umls:C0021051 | Immunologic Deficiency Syndromes | 1 | BeFree |
| umls:C0026764 | Multiple Myeloma | 1 | BeFree |
| umls:C0036690 | Septicemia | 1 | BeFree |
| umls:C0042769 | Virus Diseases | 1 | BeFree |
| umls:C0079731 | B-Cell Lymphomas | 1 | BeFree |
| umls:C0153381 | Malignant neoplasm of mouth | 1 | BeFree |
| umls:C0153676 | Secondary malignant neoplasm of lung | 1 | BeFree |
| umls:C0154251 | Lipid Metabolism Disorders | 1 | BeFree |
| umls:C0206669 | Hepatocellular Adenoma | 1 | CTD_human |
| umls:C0220641 | Lip and Oral Cavity Carcinoma | 1 | BeFree |
| umls:C0238461 | Anaplastic thyroid carcinoma | 1 | BeFree |
| umls:C0243026 | Sepsis | 1 | BeFree |
| umls:C0262587 | Parathyroid Adenoma | 1 | BeFree |
| umls:C0282528 | Peroxisomal Disorders | 1 | BeFree |
| umls:C0333186 | Restenosis | 1 | BeFree |
| umls:C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | BeFree |
| umls:C0524620 | Metabolic Syndrome X | 1 | CTD_human |
| umls:C0598935 | Tumor Initiation | 1 | BeFree |
| umls:C0699790 | Colon Carcinoma | 1 | BeFree |
| umls:C0751956 | Acute Cerebrovascular Accidents | 1 | BeFree |
| umls:C0854467 | Myelosuppression | 1 | BeFree |
| umls:C0857007 | Hyperbilirubinemia, Neonatal | 1 | BeFree |
| umls:C0860204 | Cholestatic liver disease | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | GAD |
| umls:C1512409 | Hepatocarcinogenesis | 1 | BeFree |
| umls:C1519689 | Tumor Promotion | 1 | BeFree |
| umls:C1865868 | ALZHEIMER DISEASE 5 | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |